Thrombogenic risk factors (blood coagulation disorders and thrombophilia) are the cause of cardiovascular diseases, among which genetic factors are worth highlighting (genetic polymorphism of the blood coagulation system, angiogenesis factors, and components of the lipid metabolism system). Early identification of clinically significant polymorphisms in genes that cause predisposition to thrombogenic diseases allows for preventive measures and timely diagnosis even before the onset of the clinical picture of the disease, and for patients with an already confirmed diagnosis, genetic diagnostics makes it possible to check the hereditary nature of the disease, select treatment tactics, and predict the risk of developing of adverse drug reactions. This article describes the process of developing the "SNP2-TMG" kit, designed to identify ten genetic markers of susceptibility to thrombogenic diseases (rs1801131, rs6025, rs11549465, rs429358, rs7412, rs1799963, rs6050, rs1799762, rs2010963, and rs1801133), by the minisequencing technique (SNaPshot technology). This kit has passed clinical trials and is approved for medical use.